VINS Bioproducts Limited, an immunological company based in Hyderabad, has received approval from the Drugs Controller General of India (DCGI) to carry out clinical trials to test its Covid-19 treatment candidate VINCOV-19. The phase I and II trials of the VINCOV-19 was developed in collaboration with the Center for Cellular and Molecular Biology (CCMB) and the University of Hyderabad (UoH).
The preclinical trials of VINCOV-19 commenced in October 2020 which proved to be successful as it was conducted on rodents and non-rodents. It was able to develop F(ab’)2 polyclonal antibodies that revealed high COVID-19 neutralising capacity.
Developing Immunogenicity in horses
Categorised as a therapeutic product, the Covid-19 treatment candidate has been developed by vaccinating horses by increasing its glycoprotein of the inactivated Covid virus. The outcome of the process led to the development of antibodies in the horses, which in turn shows that this candidate can be injected into humans who are infected with Covid-19 to neutralise the virus.
High ability to neutralise the virus
As part of development, VINS Bioproducts preferred the inactivated virus domain of the SARS-CoV-2 Spike protein as an immunogen. The results signified that the company’s product has a high potential and ability to neutralise the virus. Neutralising antibodies could block the internalisation of SARS-CoV-2 to lung cells, hence, it is being stated that passive administration to the patients in the initial stage of infection should render maximum clinical benefits against the disease.
Safety & Efficacy to be tested on 300 subjects
The clinical trials of VINCOV-19 will involve more than 300 subjects from across the country. The safety and effectiveness of the antibodies will be evaluated in a cohort of 300 patients infected with Covid-19. The clinical plan is to administer the hyperimmune serum to patients who will indicate moderate to severe symptoms according to the Covid-19 treatment guidelines.
While the viral antigen is developed by the Center for Cellular and Molecular Biology (CCMB), the University of Hyderabad has helped with the product characterisation and VINS bioproducts carried out the equine immunisation and clinical developments. This strengthens the idea that the therapeutic strategy, with equine antibodies, will play a significant role in managing Covid-19 infections in the country.
VINS Bioproducts Limited: An Overview
VINS bioproducts company was set up in 1997, deals in developing life-saving antiserum or antidote against snake and scorpion bites as well as tetanus, diphtheria and rabies immunoglobulins. The established company supplies the antiserum to over 70 countries as well as deals with international organisations like World Health Organisation, United Nations International Children’s Fund and United Nation Development Programme.